Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 1999

View Archived Issues

Intratumoral IFN-gamma via retroviral vector assessed in metastatic melanoma

NIDA study sheds new insight on cocaine addiction process

Phakellistatins 10 and 11 available for licensing from ASU

Neristatin 1 available for licensing from ASU

Bristol-Myers Squibb enters target validation collaboration with Exelixis

Genelabs achieves positive results in pivotal trial of GL-701 for treatment of lupus

FDA gives Vasogen go-ahead for TAA trial

SciClone awarded U.S. patent for hepatitis B combination therapy

Baclofen offers promise in migraine prevention

Bayer licenses novel penem prodrug in phase II testing

Discovery Laboratories reaches first marketing agreement for osteoporosis drug

Preclinical study results support potential of NK1 antagonist in treating micturition disorders

Phase II study evaluating oral levalbuterol now under way in Canada

Screening by Japanese researchers leads to identification of FJ-5002 as potent telomerase inhibitor

Pharmacological profile of FR-145715, a new H2 antagonist, studied using in vitro and in vivo models

FDA accepts IND for ImmunoGen's tumor-activated prodrug

New analgesic/antiinflammatory medicines claimed by Sankyo

TNP-470 evaluated in patients with metastatic renal carcinoma

Cytokine production modulators identified as part of Japanese pharmaceutical collaboration

Leteprinim provides therapeutic benefit in SDAT patients in 28-day study

Antihyperglycemic effects of novel imidazoline derivative investigated

Results of open-label study of topiramate in bipolar disorder justify additional trials

New antitumor antibiotic discovered by Yamanouchi

European researchers describe novel mechanism of action for MPB-07 and MPB-27

MedImmune to acquire U.S. Bioscience

Naphthoquinones from Fuji Photo Film exhibit immunosuppressive and antiarthritic activity

Potentially beneficial cardiovascular effects of raloxifene uncovered

BTS-79018, a potent antipsychotic agent with an improved side effect profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...